Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Amarex Clinical Research guides its client to phase II of FDA trials
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Sam Samad will be departing Illumina on July 8, 2022, after serving as CFO for more than five years.
Company hires life science veteran Jessica Cao to join management team
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
Subscribe To Our Newsletter & Stay Updated
